Gene Therapy to Target KK-LC-1 for Oncology is under clinical development by T-Cure Bioscience and currently in Phase I for Gastric Cancer. According to GlobalData, Phase I drugs for Gastric Cancer have a 79% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Gene Therapy to Target KK-LC-1 for Oncology’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Gene Therapy to Target KK-LC-1 for Oncology overview

Gene therapy is under development for the treatment of solid tumors including cervical cancer, gastric, lung, breast, epithelial, triple-negative breast, liver, non-small cell lung and pancreatic cancer. The drug candidate consists of viral vector and comprises of autologous T cells are engineered to express T cell receptor (TCR), which targets cells expressing Kita-Kyushu lung cancer antigen 1 (KK-LC-1). The drug candidate is developed based on TCR discovery iSORT platform. It is administered through intravenous route.

T-Cure Bioscience overview

T-Cure Bioscience, a biotechnology company that engaged in developing autologous T cell receptor (TCR) therapy products for the treatment of solid tumors. The company is headquartered in United States.

For a complete picture of Gene Therapy to Target KK-LC-1 for Oncology’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.